MedChemExpress - Model Artemether - 71963-77-4

FromMedChemExpress LLC (MCE)

Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria[1].

Artemether

MCE China：Artemether

Brand：MedChemExpress (MCE)

Cat. No.HY-N0402

CAS：71963-77-4

Synonyms：Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224

Purity：98.42%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria.

In Vitro：Artemether (0-200 μg/mL, 24-72 h) inhibits rat C6 glioma cell growth in a dose- and time-dependent manner[2]. Artemether (0-10 μM, 72 h) inhibits RANKL-induced osteoclast (osteoclast precursor cells (BMMs)) formation and related gene expression (TRAP, NFATc1, V-ATPase-d2, CTSK, DC-STAMP, MMP-9)[2]. Artemether (48 or 96 h) inhibits ConA- or alloantigen-induced BALB/c splenocyte proliferation (IC50: 6.3 and 3.5 μM)[4]. Artemether (0-50 μM, 16-36 h) inhibits production of the IL-2 and IFN-γ in BALB/c splenocyte[4]. Artemether (0-50 μM, 72 h) inhibits ConA-induced splenocyte, CD4+T- and CD8+ T-cell divisions, and inhibits cell cycle progression through G1/S transition[4].

In Vivo：Artemether (0-66 mg/kg, p.o.) inhibits tumor growth and angiogenesis in SD rats bearing C6 glioma cells[2]. Artemether (10 mg/kg, i.p., 8 days) protects mice against LPS-induced osteolytic bone loss[3]. Artemether (50 and 100 mg/kg, p.o.) inhibits T-cell-mediated immune responses (ear swelling) in DNFB-induced DTH model in BALB/c mice[4].

IC50 & Target：Plasmodium

References：

[1]. Xiao, S., et al., Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop, 2002. 82(2): p. 175-81. [Content Brief]

[2]. Wu, Z.P., et al., Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther, 2009. 8(1): p. 88-92. [Content Brief]

[3]. Wu H, et al. Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway. Cell Death Dis. 2018 May 1;9(5):498. [Content Brief]

[4]. Wang JX, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol. 2007 Mar;150(5):652-61. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。